Regenerative medicine is moving quickly. In 2025 and 2026, researchers reported major trial results for knee osteoarthritis, the spine, and tendon injuries, and the regulatory picture kept evolving. This article rounds up the most important recent science in plain language and explains what it means for a patient considering care in Honolulu.
Months
how long a December 2025 review found PRP benefit could last
July 2026
first U.S. Phase 3 participant treated for a cord-cell knee cartilage trial
8
patients in the STEM-PD Parkinson trial that met its primary feasibility endpoint at 12 months
For the conditions regenerative clinics see most often, the evidence supports a careful, honest message. Large 2025 reviews and meta-analyses of platelet-rich plasma (PRP) for knee osteoarthritis generally find it safe and often helpful for short-term pain and function, while a December 2025 review comparing PRP with placebo found only modest, and often temporary, benefit lasting up to about six months. Put plainly: many patients improve, but results vary and they are not guaranteed.
Reviews of bone marrow aspirate concentrate (BMAC) for knee osteoarthritis describe a safe injection with meaningful relief for many patients, though when compared head to head with other injections the differences often did not reach what researchers consider a clinically important level. Some longer follow-up studies report durable improvement, and research continues. For most people this is a symptom-modifying treatment, not a cure, which is the expectation a good clinic sets.
“PRP for knee osteoarthritis is generally safe and often helpful for short-term pain and function, but the benefit compared with placebo can be modest and may wear off over the months that follow.”
The spine produced some of the biggest headlines. A 36-month Phase III trial of cell therapy for chronic low back pain was published in 2025, and the FDA granted fast-track designations for several cell products for the disc. At the same time, the DREAM trial reminded the field that structural change does not always mean symptom relief, keeping expectations appropriately humble.
For tendons, PRP shows its strongest evidence in tennis elbow, where it outperforms corticosteroid injections over the long term, while the picture for Achilles and rotator cuff problems is more mixed. Newer work on tendon-derived cells and the signals they release is promising but still early. The reminder for patients is that not every regenerative claim matches the evidence, and the specific condition matters enormously.
As of 2025 and 2026, no stem cell or PRP product is FDA-approved for orthopedic conditions; they are considered investigational, and the FDA continues to warn against unapproved exosome and stem cell products marketed with miracle claims. The most notable development in 2026 is that the first U.S. participant was treated in MEDIPOST's Phase 3 CARTISTEM trial for knee cartilage defects in July 2026, a program that could represent a first approval of its kind if it succeeds. It remains investigational, and we have a dedicated guide to the 2026 trial landscape.
The clearest new movement is in the knee. In February 2026 the FDA cleared MEDIPOST's Phase 3 plan for CARTISTEM, an umbilical cord blood cell therapy for cartilage defects due to knee osteoarthritis, and the first U.S. participant was treated in July 2026 in a study planned across roughly 60 U.S. and Canadian sites. Steminent Biotherapeutics began a U.S. FDA-authorized Phase II trial of its own knee osteoarthritis cell therapy in March 2026. All of these remain investigational and none are FDA-approved, but together they represent the most serious late-stage U.S. study of cell therapy for the knee to date. We break the details down in a dedicated guide below.
Some of the biggest 2026 news came from outside the orthopedic world. In a Phase I/II trial published in Nature Medicine, researchers transplanted stem cell-derived dopamine-producing cells into the brains of eight patients with moderate Parkinson's disease. The trial met its primary feasibility endpoint at 12 months, with no serious graft-related adverse events and PET-confirmed graft survival, and most of the patients who completed follow-up were able to reduce their Parkinson's medication. In March 2026 the FDA approved KRESLADI, a lentiviral stem cell gene therapy for children with severe leukocyte adhesion deficiency-I, the first therapy funded by California's stem cell agency to reach FDA approval. And in September 2026 a meta-analysis of randomized cardiac trials found stem cell therapy produced modest but measurable gains in heart function and reduced infarct size.
“The Phase I/II STEM-PD trial published in Nature Medicine in 2026 met its primary feasibility endpoint at 12 months: stem cell-derived dopamine cells survived and integrated in the brain with no serious graft-related adverse events.”
What does any of this mean for a Honolulu patient weighing care for a knee or shoulder? Two things. First, the field is advancing on many fronts at once, which is exactly why honest regenerative medicine is careful and specific rather than sweeping. Second, the 2026 treatments getting the strongest evidence, from Parkinson's to heart disease, are complex, tightly regulated, and years away from mainstream orthopedic use. That only raises the bar for what a clinic should be able to show you for your specific condition, and for its own preparation methods.
Outside the clinic setting, researchers reported several genuine firsts in 2026. In July, scientists at Keio University published the world's first transplant of iPSC-derived neural stem cells into patients with subacute spinal cord injury, with up to four years of follow-up: no tumor formation or graft-related adverse events, stable graft sites on imaging, and exploratory improvements in motor scores. In February, the CuRe trial at UC Davis Health reported first-in-human results adding placenta-derived stem cells to fetal surgery for spina bifida, finding the approach safe and feasible for the babies born so far. And in the same month, Phase 2b results published in Cell Stem Cell showed that laromestrocel, a mesenchymal stem cell product given intravenously, improved physical condition in adults with age-related frailty at nine months compared with placebo.
None of these treatments is available in an office setting, and none is FDA approved. They matter to a Honolulu patient because they show where the field is heading and how rigorous the evidence for a future therapy must be, which is the same standard a good clinic applies to what it offers today.
A note from the clinic
Science moves fast, and patients deserve a clinic that keeps up honestly. At Aloha Stem Cell in Honolulu, we follow the same studies you may see in the news and translate them into an honest plan for your specific situation. Call (808) 593-2525 or book a consultation to talk through what the evidence means for you.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.